文献速递类风湿关节炎

托法替布治疗类风湿关节炎:疾病活动度早期无变化与第6个月达到低疾病活动度的概率

Tofacitinib in Rheumatoid Arthritis: Lack of Early Change in Disease Activity and the Probability of Achieving Low Disease Activity at Month 6.
PubMed 文献 · Arthritis Care Res (Hoboken) · 2019-01-01

该事后分析基于两项随机双盲III期研究,探索托法替布治疗类风湿关节炎早期疾病活动度变化与第6个月达到低疾病活动度(LDA)及缓解的关系;结果显示,甲氨蝶呤应答不佳患者使用托法替布1或3个月无应答预示第6个月达到LDA概率低,早期无应答可考虑用于决定是否继续托法替布治疗。

要点

  • ORAL Start中托法替布5mg和10mg每日两次组分别有7.2%和5.4%患者第3个月CDAI改善未达≥6,其中分别3.8%和28.6%第6个月达到CDAI定义的LDA。
  • ORAL Standard中托法替布5mg和10mg每日两次组分别有18.8%和17.5%患者第3个月CDAI改善未达≥6,其中分别0%和2.9%第6个月达到CDAI定义的LDA。
  • 甲氨蝶呤应答不佳患者使用托法替布1或3个月无应答预示第6个月达到LDA概率低,早期无应答可考虑用于决定是否继续治疗。

核心结论

  • 在甲氨蝶呤应答不佳的患者中,托法替布治疗1或3个月无应答预示第6个月达到LDA的概率低。
  • 作者认为,早期无应答可考虑用于决定是否继续托法替布治疗。

研究设计与样本

  • 事后分析,数据来自两项随机双盲III期研究。
  • ORAL Start研究中,甲氨蝶呤未治患者接受托法替布5或10mg每日两次或甲氨蝶呤治疗24个月。
  • ORAL Standard研究中,甲氨蝶呤应答不佳患者接受托法替布5或10mg每日两次或阿达木单抗40mg每2周联合甲氨蝶呤治疗12个月。

主要发现

  • ORAL Start中,托法替布5mg和10mg每日两次组分别有7.2%和5.4%患者第3个月CDAI改善未达≥6;这些未达标患者中分别有3.8%和28.6%第6个月达到CDAI定义的LDA。
  • ORAL Standard中,托法替布5mg和10mg每日两次组分别有18.8%和17.5%患者第3个月CDAI改善未达≥6;这些未达标患者中分别有0%和2.9%第6个月达到CDAI定义的LDA。
  • 考虑第1个月改善或DAS28-ESR阈值时,结果相似。

关键数值与推荐

  • LDA定义:CDAI评分≤10或基于红细胞沉降率的28关节疾病活动度评分(DAS28-ESR)≤3.2。
  • 阈值改善定义:CDAI较基线变化≥6或DAS28-ESR较基线变化≥1.2。
  • 评估时间点:第1个月或第3个月未达到阈值改善,计算第6个月和第12个月达到LDA的概率。

临床怎么用

  • 作者认为,早期无应答可考虑用于决定是否继续托法替布治疗。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Optimal targeted treatment in rheumatoid arthritis requires early identification of failure to respond. This post hoc analysis explored the relationship between early disease activity changes and the achievement of low disease activity (LDA) and remission targets with tofacitinib. METHODS: Data were from 2 randomized, double-blind, phase III studies. In the ORAL Start trial, methotrexate (MTX)-naive patients received tofacitinib 5 or 10 mg twice daily, or MTX, for 24 months. In the placebo-controlled ORAL Standard trial, MTX inadequate responder patients received tofacitinib 5 or 10 mg twice daily or adalimumab 40 mg every 2 weeks, with MTX, for 12 months. Probabilities of achieving LDA (using a Clinical Disease Activity Index [CDAI] score ≤10 or the 4-component Disease Activity Score in 28 joints using the erythrocyte sedimentation rate [DAS28-ESR] ≤3.2) at months 6 and 12 were calculated, given failure to achieve threshold improvement from baseline (change in CDAI ≥6 or DAS28-ESR ≥1.2) at month 1 or 3. RESULTS: In ORAL Start, 7.2% and 5.4% of patients receiving tofacitinib 5 and 10 mg twice daily, respectively, failed to show improvement in the CDAI ≥6 at month 3; of those who failed, 3.8% and 28.6%, respectively, achieved month 6 CDAI-defined LDA. In ORAL Standard, 18.8% and 17.5% of patients receiving tofacitinib 5 and 10 mg twice daily, respectively, failed to improve CDAI ≥6 at month 3; of those who failed, 0% and 2.9%, respectively, achieved month 6 CDAI-defined LDA. Findings were similar when considering improvements at month 1 or DAS28-ESR thresholds. CONCLUSION: In patients with an inadequate response to MTX, lack of response to tofacitinib after 1 or 3 months predicted a low probability of achieving LDA at month 6. Lack of an early response may be considered when deciding whether to continue treatment with tofacitinib.

来源:Arthritis Care Res (Hoboken),查看原文。版权归原作者所有。

引用

  1. van Vollenhoven RF, Lee EB, Fallon L, et al. Tofacitinib in Rheumatoid Arthritis: Lack of Early Change in Disease Activity and the Probability of Achieving Low Disease Activity at Month 6. Arthritis Care Res (Hoboken). 2019. PMID: 29696833. doi:10.1002/acr.23585

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。